M Holdings Securities Inc. Makes New $637,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

M Holdings Securities Inc. bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, HoldingsChannel reports. The fund bought 15,965 shares of the company’s stock, valued at approximately $637,000.

A number of other hedge funds also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after buying an additional 1,004,941 shares during the last quarter. WCM Investment Management LLC grew its position in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares during the period. Wellington Management Group LLP grew its position in Teva Pharmaceutical Industries by 5.8% during the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after buying an additional 419,329 shares during the period. Janus Henderson Group PLC increased its holdings in Teva Pharmaceutical Industries by 1.5% during the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock worth $145,076,000 after buying an additional 72,880 shares during the last quarter. Finally, Bessemer Group Inc. increased its holdings in Teva Pharmaceutical Industries by 1.6% during the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock worth $131,036,000 after buying an additional 70,058 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 1.4%

NYSE:TEVA opened at $42.38 on Wednesday. The company has a market cap of $49.38 billion, a P/E ratio of 98.55, a P/E/G ratio of 4.04 and a beta of 0.97. The stock’s fifty day moving average price is $39.75 and its two-hundred day moving average price is $34.90. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $43.34. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the company earned $0.78 earnings per share. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 420,942 shares of company stock valued at $16,572,473. Corporate insiders own 0.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on TEVA. HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They issued a “buy” rating and a $52.00 price objective on the stock. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. Oppenheimer raised their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, October 9th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Finally, Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $47.23.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.